| The U.S. Food and Drug Administration approved Xgeva (denosumab) on Thursday to help prevent skeletal-related events (SREs) in patients with cancer that has spread (metastasized) and damaged the bone. Skeletal-related events include bone fractures from cancer and bone pain requiring … Continue reading |
|
The post Xgeva, helps prevent cancer-related bone injury, OKd by FDA appeared first on Health, Medical, and Science Updates.